A patient-derived bladder cancer organoid and xenograft platform for personalized drug response prediction and salvage therapeutics screening

医学 膀胱癌 类有机物 肿瘤科 内科学 个性化医疗 药物反应 药品 一致性 癌症 临床试验 功效 转录组 癌症研究 精密医学 药物重新定位 生物标志物 抗药性 细胞毒性 曲美替尼 液体活检 癌细胞 药理学 癌细胞系 帕纳替尼 免疫疗法 药物发现 抗癌药物
作者
Lu Junlin,Kaiwen Jie,Chu Liu,Lai Jiajian,Xu Peng,Xinxin He,Xiao Kanghua,Chen Yating,Liu Sen,Chen Zehua,Jianhui Zhang,Yang Zegeng,Lin Shizhi,Zhang Qiang,Huang Ming,Cheng Liang,Siting Chen,Jianmei Zhong,Li Sheng,Li Hong
出处
期刊:Chinese Journal of Cancer Research [AME Publishing Company]
卷期号:38 (4): 661-678
标识
DOI:10.21147/j.issn.1000-9604.2026.05.11
摘要

Objective: Therapeutic resistance remains a major challenge in bladder cancer treatment. The aim of this study was to develop and validate a bladder cancer patient-derived organoid (PDO)-based platform for treatment response prediction and individualized salvage therapy screening. Methods: A total of 101 patients with bladder cancer were enrolled to establish 75 PDO lines. The optimal culture medium was determined by transcriptome analysis. Consistency validation was performed via histopathology, immunohistochemistry, whole-exome sequencing, and transcriptomic profiling. A three-step high-throughput screening pipeline for 288 approved agents was developed to identify salvage therapies for patients who were multidrug-resistant, which was validated in patient-derived xenograft (PDX) models. A suspension coculture system was constructed to evaluate HER2-targeted chimeric antigen receptor T (CAR-T) cell cytotoxicity and activation. Results: FGF4 supplementation significantly enhanced the 3D growth and establishment efficiency of PDOs, yielding a biobank of 75 bladder cancer PDOs. These PDOs faithfully recapitulated the multidimensional features of parental tumors, and showed preliminary concordance with observed clinical treatment responses (cisplatin, gemcitabine, and epirubicin). To address drug resistance, the high-throughput drug screening pipeline maps individualized sensitivity profiles in four cases. In a patient who was multidrug-resistant, idarubicin was pinpointed as a potent candidate agent, with efficacy confirmed in PDX models. To extend the screening platform beyond chemotherapeutics and cover cellular immunotherapies, we verified that the coculture system enabled HER2 expression-dependent CAR-T cytotoxicity evaluation. Conclusions: This integrated bladder cancer PDO platform provides a clinically relevant individualized tool for treatment response prediction and individualized salvage therapy selection, particularly for patients with multidrug-resistant disease. Its application may support tailored therapeutic decision-making across chemotherapy, targeted therapy, and cellular immunotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被最喜欢喝芭乐奶茶采纳,获得10
刚刚
刚刚
刚刚
1秒前
喝掉一只鞋完成签到,获得积分10
2秒前
如意以旋发布了新的文献求助20
2秒前
所所的应助被sherry采纳,获得10
3秒前
科研通AI2S的应助被111采纳,获得10
3秒前
还不是尽头完成签到,获得积分10
3秒前
4秒前
unn完成签到,获得积分20
4秒前
贝贝贝贝完成签到,获得积分10
4秒前
Jun的应助被小花花采纳,获得10
5秒前
122mm鲱鱼罐头关注了科研通微信公众号
5秒前
5秒前
自由的寒蕾完成签到,获得积分10
5秒前
5秒前
6秒前
6秒前
11223完成签到 ,获得积分10
6秒前
6秒前
7秒前
yuan发布了新的文献求助10
8秒前
8秒前
9秒前
菠菠发布了新的文献求助10
9秒前
无情丹秋发布了新的文献求助10
9秒前
曈12完成签到 ,获得积分10
9秒前
wanci的应助被yangyang采纳,获得10
10秒前
缄默完成签到,获得积分10
10秒前
chiyudawang发布了新的文献求助10
10秒前
orixero的应助被杰帅采纳,获得20
10秒前
庄艺斌发布了新的文献求助10
11秒前
12秒前
Jasper的应助被科研通管家采纳,获得10
12秒前
12秒前
Elva完成签到,获得积分20
12秒前
所所的应助被科研通管家采纳,获得20
12秒前
科目三的应助被科研通管家采纳,获得100
12秒前
丘比特的应助被阿Q采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178048
求助须知:如何正确求助?哪些是违规求助? 9568764
关于积分的说明 21801331
捐赠科研通 7772794
什么是DOI,文献DOI怎么找? 3432613
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478151